ResearcherHiroshima UniversityActive in the last 2 years
Shinya Takahashi
Matched on OpenAlex author ID A5134436700. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2026: 4 papers
Papers 4
- Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. Last author DOI 10.1002/jhbp.70113↗
- Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors. Co-author DOI 10.1007/s12328-026-02388-z↗
- TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20228-9↗
- ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20329-5↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Takeshi Sudo · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Yosuke Shimizu · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Hirotaka Tashiro · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Kenta Baba · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Tatsuaki Sumiyoshi · 2 shared papers, 2026 · strength 0.59
- Paper Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. DOI 10.1002/jhbp.70113↗
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Kenichiro Uemura · 2 shared papers, 2026 · strength 0.59
- Paper Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. DOI 10.1002/jhbp.70113↗
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Kaoru Seo · 1 shared paper, 2026 · strength 0.30
- Yoshiaki Murakami · 1 shared paper, 2026 · strength 0.30
- Kenjiro Okada · 1 shared paper, 2026 · strength 0.30
- Ryuta Shintakuya · 1 shared paper, 2026 · strength 0.30
- Sho Tazuma · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.